Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 DDI Study with Sulfasalazine in Healthy Adults
NCT04720183Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLPG3970 in rheumatoid arthritis (RA), ulcerative colitis (UC) and psoriasis, sponsored by Galapagos NV. Primary endpoints: Maximum observed concentration (Cmax) of sulfasalazine, Maximum observed concentration (Cmax) of sulfapyridine and 3 more. Started Jan 2021; status: completed.
02
Drugs
GLPG3970
03
Conditions
rheumatoid arthritis (RA)ulcerative colitis (UC)psoriasis
Beyond the preview
Go deeper on NCT04720183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720183.